Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...
The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...
This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".
The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...
The drug is administered via injection and offers long-lasting efficacy, with a monthly maintenance dose required after the ...
Overview: Eli Lilly and Company discovers ... Recent FDA approval for new treatments like EBGLYSS and positive trial results bolster its financial outlook amidst executive changes and strategic ...
1d
Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...
According to Benzinga Pro, Eli Lilly's peer group average for short interest as a percentage of float is 4.49%, which means ...
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
INDIANAPOLIS–The U.S. Food and Drug Administration has approved Eli Lilly’s new treatment for moderate to severe eczema. It’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback